NE HEALTH BUREAU
BENGALURU, MAY 20
In a major healthcare and biotechnology breakthrough for India and South Asia, Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched the region’s first Olink™ Explore HT proteomics service, marking a transformative leap in precision medicine, disease research and next-generation healthcare innovation.
The launch significantly strengthens India’s capabilities in large-scale multi-omics research — an advanced scientific approach that combines genomics, proteomics and clinical data to better understand diseases and develop targeted treatments.
- Strand Life Sciences launches South Asia’s first Olink™ Explore HT proteomics service for large-scale multi-omics research
- New platform can analyse over 5,400 protein biomarkers using just 2 µL blood sample, enabling faster disease insights
- Advanced technology expected to transform precision medicine, drug discovery and translational research in India and the region
- Strand successfully completes chronic kidney disease proteomics project for a biopharma partner, showcasing real-world clinical potential
- Integrated genomics, proteomics and clinical data approach positions India as a growing hub for next-generation healthcare research
A New Window Into Human Disease
Every living cell in the human body produces thousands of proteins that regulate critical biological functions ranging from immunity and metabolism to organ function and disease progression.
Proteomics, the large-scale study of these proteins, allows scientists to understand how diseases evolve inside the body and how treatment responses vary among patients.
Unlike conventional diagnostics, next-generation proteomics platforms can simultaneously analyse thousands of proteins from a tiny blood sample, providing faster and more detailed insights into disease biology.
Experts believe this could revolutionise early diagnosis, personalised treatment selection and drug discovery across multiple diseases including cancer, kidney disorders, metabolic diseases and rare illnesses.
Tiny Blood Sample, Massive Medical Insights
The newly launched Olink™ Explore HT platform enables the measurement of more than 5,400 protein biomarkers from just 2 microlitres of blood sample — nearly one-twenty-fifth of a single drop of blood.
This allows researchers to generate highly detailed biological data while reducing sample requirements for patients.
For pharmaceutical and biotechnology companies, the platform offers the ability to compress lengthy research programmes into integrated, large-scale studies, significantly accelerating clinical research and therapeutic development timelines.
For patients and clinicians, the implications are equally promising as proteomics-driven biomarkers could improve treatment precision and help identify diseases at much earlier stages.
Strand Completes Kidney Disease Research Project
Demonstrating the practical potential of the technology, Strand has already completed a proteomics research project for a biopharma partner involving patients with chronic kidney disease.
The successful study highlights how integrated multi-omics research can support translational medicine and improve understanding of complex diseases.
With its extensive network of clinical collaborators, the company is now preparing to support large-scale studies involving diverse patient populations across India, South Asia and West Asia.
Research areas include oncology, nephrology, metabolic disorders and rare diseases.
“One of the World’s Most Advanced Proteomics Platforms”
Dr. Ramesh Hariharan, CEO of Strand Life Sciences, said:
“With Olink™ Explore HT, Strand is bringing one of the world’s most advanced proteomics platforms to India and the region. By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes and enable faster, more impactful discovery. We welcome collaborations with global pharma and biotech partners to accelerate research and development pipelines.”
India Emerging as Global Multi-Omics Research Hub
With the launch, Strand is offering:
- Access to over 5,400 protein biomarkers through Olink™ Explore HT
- Seamless integration of genomics and clinical datasets
- End-to-end support from study design to advanced data analysis
- Expertise in conducting large cohort-based studies across diverse populations
Industry experts say the growing demand for integrated multi-omics data worldwide is opening new opportunities for India to emerge as a global biotechnology and precision healthcare research destination.
Strand’s early adoption of the advanced proteomics platform is expected to strengthen India’s position in high-impact biomedical discovery programmes and next-generation therapeutic innovation.
